<DOC>
	<DOCNO>NCT02736539</DOCNO>
	<brief_summary>This study design randomized double-blinded treatment trial among traveler ' geographical area moderate-severe rate traveler 's diarrhea . Travelers randomize receive Bimuno® mask placebo take daily travel . The test article placebo take start 7 day prior travel .</brief_summary>
	<brief_title>Clinical Trial CBS-2004 ( Bimuno ) ® Prevention Travelers ' Diarrhea</brief_title>
	<detailed_description />
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Dysentery</mesh_term>
	<criteria>1 . Healthy subject , 18 year old old 2 . Travel moderatehigh risk itinerary traveler 's diarrhea minimum 14 day maximum 6 week travel 3 . Able comply study followup procedure 4 . Subjects willing able enter data diary card 5 . An IRB approve informed consent form sign dated 6 . Subjects must adequate general health ( determined investigator ) 7 . Women : Nonnursing negative urine/serum pregnancy test understanding informed consent process avoid pregnancy study study drug . Should individual document surgical sterilization medical record , pregnancy test require . If volunteer becomes pregnant study , Principal Investigator ( PI ) notify study research monitor Institutional Review Boards ( IRBs ) . The pregnancy outcome follow per IRB regulatory requirement . 1 . Allergy investigational product 2 . History functional bowel disorder ( include IBS ) 3 . Chronic intestinal disease ( ulcerative colitis , crohn 's disease ) , post vagotomy diabetic autonomic neuropathy , malabsorption , short bowel syndrome , celiac disease , bacterial overgrowth due blind loop , pancreatitis 4 . Antibiotic use within 7 day prior enrollment ( except malaria prophylaxis exclude doxycycline ) 5 . Use probiotic prebiotics ( outside study product ) prior 3weeks intent use study period . This include overthecounter preparation probiotic , prebiotics ( include inulin , lactulose ) consumption bioyogurt product . 6 . Lactose intolerant ( allergy dairy product ) . 7 . Medications usage deem PI interfere GI function 8 . Diarrheal illness within 7 day prior enrollment 9 . Subject concomitant disease condition could interfere treatment could interfere conduct study , could opinion investigator increase risk adverse event ( AEs ) subject 's participation study . 10 . Use investigational nonregistered drug study drug within 30 day precede study enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>